Barbara S. Schilberg

Jenrin Discovery, Inc. develops therapeutics for chronic diseases. It provides therapeutics for various diseases, including obesity, diabetes, and autoimmune and inflammatory disorders. The company was founded by John F. McLeroy on April 17, 2007 and is headquartered in Philadelphia, PA.

Marillion Pharmaceuticals, Inc. provides cancer pharmaceuticals. It focuses on the development and commercialization of novel therapeutics for the treatment of cancers and for care in oncology. The firm products include Lu-AMBA, Pilobuc, and MN-201. The company was founded by Jerry Glickson, Zahed Subhan, and Gang Zheng in February 2005 and is headquartered in Radnor, PA.

Mebias Discovery, LLC engages in discovering drugs. The company was founded by Lawrence C. Kuo, Brett A. Tounge and Shariff S. Bayoumy in January 2016 and is headquartered in Philadelphia, PA.

The Biotechnology Greenhouse Corp. of Southeastern PA (BioAdvance) is a venture capital firm founded in 2002. The firm is headquartered in Philadelphia, Pennsylvania.

Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA.

PhenoTech, Inc. develops and markets monoclonal antibodies which are used in blood diagnostic and therapeutic applications. It offers blood diagnostic reagents, such as nanoscale emissive antibody-complexes for typing reagents for pre-transfusion testing. The company was founded by Eric Ostertag in 2003 and is headquartered in Philadelphia, PA.

Locus Pharmaceuticals is a pharmaceutical company focused on developing novel, small molecule therapeutics to address major unmet medical needs. Locus utilizes powerful and proprietary computational technologies running on Linux-based supercomputer clusters to simultaneously identify relevant binding sites on protein disease targets and rapidly generate novel, small molecules that bind specifically to those protein sites. In contrast to other computational approaches, the Locus technology requires only a high-resolution, 3-dimensional structure of the target protein to implement its drug discovery process. Locus Pharmaceuticals is synthesizing and testing novel drug candidates for the treatment of debilitating and life-threatening human diseases, including HIV/AIDS, cancer, arthritis and inflammation.